CEO
Connor Wander, PhD, is a Research Scientist at Deciduous Therapeutics, Inc and a recent graduate from the Pharmacology Department at UNC Chapel Hill. As a co-mentored student between the Cohen and Song Labs at UNC, Connor studied glial biology, adult neurogenesis, and inhibitory neural networks in Alzheimer’s Disease. His other scientific interests include the interactions between the environment, genetics, and nutrition in neurodegenerative diseases. Connor and Julian founded SFS with the idea of connecting people directly with scientists.
Outside of the lab, Connor enjoys hobbies such as graphic design, balcony gardening, gaming, Brazilian Jiu Jitsu, paintball and caring for his bearded dragons.
Education
PhD in Pharmacology
UNC Chapel Hill 2021
B.S. In Biology and Biochemistry — Chemistry Minor
Virginia Tech 2014
Connor Wander’s Publications
- Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease
- The neurogenic niche in Alzheimer's disease
- Neuropeptides Modulate Local Astrocytes to Regulate Adult Hippocampal Neural Stem Cells
- The Accumulation of Tau-Immunoreactive Hippocampal Granules and Corpora Amylacea Implicates Reactive Glia in Tau Pathogenesis during Aging
- A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation
- Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program
- A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy
Gallery
